1 2 Objective: To describe transfusion practices and blood loss severity in women with 3 postpartum haemorrhage (PPH), according to the clinical context. 4 Design: Population-based cohort study 5 Setting: 106 French maternity units (146781 deliveries, December 2004-November 2006) 6 Population: All women with PPH (n=9365) 7
Introduction 1 2
Postpartum haemorrhage (PPH) is a common complication of delivery whose incidence 3 has increased recently in several countries (1-4). PPH is associated with substantial maternal 4 morbidity and mortality (5). In high-resource countries, PPH is the main obstetrical reason for 5 intensive care unit (ICU) admission, and the rates of severe adverse outcomes after PPH, such 6 as hysterectomy, have also increased recently (2, 5) . Progression from excessive to severe 7 haemorrhage is probably dependent not only on individual characteristics of women and 8 deliveries, but also on factors related to medical care (6). Transfusion is an important part of 9 PPH management, especially in case of on-going haemorrhage. The goals of appropriate 10 blood product transfusion are to maintain circulating blood volume and tissue oxygenation 11 and to prevent or reverse coagulopathy. The lack of access to blood products can result in 12 death of the mother (7) . Better knowledge of transfusion practices in PPH may help to 13 understand the impact on maternal outcomes. 14 Several studies have evaluated transfusion practices in women with PPH (3, 8-15). 15
However, these studies either used a single-centre retrospective design (8-11), and therefore 16 had limited external validity, or relied on hospital discharge databases, which were not 17 designed for clinical research (3, 15) . Transfusion practices were also described in recent 18 nationwide prospective observational studies, but only as secondary outcomes and in women 19 requiring invasive second-line treatments for PPH (12) (13) (14) . Information on transfusion 20 practices is needed to identify situations associated with specific blood-product needs and to 21 understand the reasons for these specific needs. This information is also necessary to optimise 22 healthcare resource allocation and to improve PPH management. 23 8 Our objective here was to describe transfusion practices and blood loss severity in 1 women with PPH, overall and in subgroups defined based on obstetrical contexts, in a large 2 population-based cohort of women with PPH in France. The source population was the cohort of women included in the Pithagore6 trial, a 8 cluster-randomised trial performed in 106 French maternity units grouped into six regional 9 perinatal networks (16) and accounting for 20% of all deliveries in France. A 1998 French 10 statute aimed at optimising the organisation of obstetric care requires every maternity unit to 11 belong to a perinatal network built around one or more level-three units (reference centres 12 with an onsite neonatal ICU) and including level-1 units (no facilities for non-routine neonatal 13 care) and level-2 units (with a neonatal care unit), whether public or private. Among the 106 14 maternity units in Pithagore6, 11% were in university hospitals, 56% in non-teaching public 15 hospitals, and 33% in non-teaching private hospitals; 56% were level 1, 36% level 2, and 8% 16 level 3. The annual number of deliveries was less than 500 in 14% of the maternity units, 17
between 500 and 1500 in 46%, and greater than 1500 in 40%. Data were collected over 1 year 18 in each unit, between December 2004 and November 2006. The aim of Pithagore6 was to 19 evaluate a multifaceted educational intervention for reducing the rate of severe PPH. As no 20 significant differences in severe PPH rates were found between the groups (16), all 21 participants were pooled in a single cohort of women with PPH. 22
In the Pithagore6 trial, PPH was assessed clinically by the medical staff or defined as a 23 greater than 2.0 g/dL decline in the haemoglobin level. The clinical definition of PPH was 24 blood loss greater than 500 mL or excessive blood loss prompting manual removal of the 25 placenta or examination of the uterine cavity (or both). The prepartum haemoglobin was 1 collected as part of routine prenatal care during the last few weeks of pregnancy. Postpartum 2 haemoglobin was the lowest haemoglobin found within 3 days of delivery (nadir of 3 haemoglobin), whether the woman had been transfused or not before. It was neither measured 4 routinely, nor as part of the study protocol. Instead, the decision was left to the clinicians. 5
Birth attendants in each unit identified all women with PPH and reported them to the research 6 team. Additionally, a research assistant reviewed the delivery-suite logbook of each unit 7 monthly and checked any available computerised woman charts. For each woman with a note 8 of PPH, uterine cavity examination, or manual removal of the placenta, the obstetric ward file 9 was reviewed to verify the diagnosis of PPH. During the study period, among 146,781 10 deliveries, 9365 (6.4%) were complicated by PPH, including 6660 (71.1%) diagnosed 11 clinically and 2705 (28.9%) diagnosed only on a haemoglobin decline ( Figure 1) . 12
By definition, women with PPH defined by a haemoglobin decline, with no clinical 13 diagnosis of PPH, did not receive specific acute care for PPH. Consequently, in our study, 14 these women were excluded from the analysis of transfusion practices and blood loss severity. 15
Our analysis was thus restricted to women with clinical PPH requiring red blood cell (RBC) 16 transfusion within 12 hours after the diagnosis (clinical PPH with early transfusion, clinical 17 PPH with early transfusion group, n=426). Indeed, this situation indicates significant acute 18 PPH, where transfusion is an essential part of the management and can be lifesaving. 19
20

Study variables 21
During the Pithagore6 trial, a standardised case-report form was used to extract data 22 from the medical chart of each woman with PPH. 23
We looked at compliance with 2002 national French transfusion guidelines (17) and 24
2004 French guidelines on PPH management (18). These guidelines indicate that RBCs 25 should be transfused when the haemoglobin level is lower than 7.0 g/dL, especially in case of 1 acute anaemia. The haemoglobin concentration should be interpreted according to blood loss 2 and vital signs and should be kept between 7.0 and 10.0 g/dL as long as the haemorrhage 3 continues. RBC transfusion is usually unnecessary when the haemoglobin level is greater than algorithm in each maternity unit were not collected in the Pithagore6 trial. However, such 10 algorithms are not intended to modify national guidelines but instead to describe local 11 implementation modalities. 12
The following baseline characteristics were recorded: maternal age in years, body 13 mass index (weight (Kg)·[height (m)] -²), primiparity, prior PPH, previous caesarean section, 14 and multiple pregnancy, all handled as binary variables; gestational age in, and prenatal 15 haemoglobin level (g/dL). We also recorded the characteristics of the delivery: epidural or 16 spinal analgesia/anaesthesia (binary variable); mode of delivery in four categories 17 (spontaneous vaginal delivery, operative vaginal delivery, caesarean section before labour, 18 caesarean section during labour); birth weight (grams), and postpartum haemoglobin 19 measurement (binary variable). PPH was documented using the time from delivery to PPH as 20 a continuous variable. The cause of PPH was recorded using five categories: coagulation 21 disorders, trauma, abnormal placenta insertion, uterine atony or retained tissues, and 22 unidentified cause. In PPH due to multiple causes, only one cause was recorded, in the order 23 reported above. 24 12 Transfusion was studied during the whole postpartum hospital stay. We evaluated the 1 nature of the blood product (RBC, fresh frozen plasma [FFP], platelets) or blood-derived 2 product (fibrinogen concentrates) administered, use of the RBC+FFP+platelet+fibrinogen 3 combination, and use of massive transfusion (10 or more RBC units), all studied as binary 4 variables. The transfused volume of each blood product (in units) and the fibrinogen dose (g) 5 administered were studied as continuous variables. In women who received both RBC and 6 FFP, the FFP/RBC ratio was computed and analysed both as a continuous variable and as a 7 categorical variable (FFP/RBC ratio of 0.5 or more and FFP/RBC ratio less than 0.5). The 8 administration of pro-haemostatic agents (recombinant activated factor VII, other synthetic 9 coagulation factors, tranexamic acid, anti-thrombin III, aprotinin) was handled as a binary 10 variable. Time from PPH diagnosis to RBC transfusion initiation was analysed as a 11 continuous variable. Acute adverse events of transfusion were looked for specifically in the 12 medical chart, where they were spontaneously reported. 13
Concerning blood loss severity, the nadir of haemoglobin and the greatest haemoglobin 14 (g/dL) drop versus baseline were studied as continuous variables. Secondary disseminated 15 intravascular coagulation (DIC), defined as a coagulation disorder not present before the 16 diagnosis of PPH (platelet count less than 50·10 3 ·mm -3 , or prothrombin time less than 50%, or 17 combination of platelet count between 50 and 100·10 3 ·mm -3 and/or prothrombin time 18 between 50% and 65% and/or fibrinogen level less than 1 g/L), was studied as a binary 19 variable. Components of the second-line management of PPH were handled as binary 20 variables; these components included arterial embolisation, conservative surgery (vascular 21 ligation and/or uterine suture), hysterectomy, and ICU admission. The rate of blood transfusion was calculated for all deliveries and for all PPH cases 1 during the study period, overall and according to the mode of diagnosis of PPH and to the 2 mode of delivery (vaginal or caesarean delivery). 3
We calculated the rates of haemoglobin measurements and of RBC transfusion among 4 women with haemoglobin levels lower than 7.0 g/dL and among those with haemoglobin 5 levels lower than 6.0 g/dL. 6
The characteristics of the women, pregnancies, and deliveries were compared between 7 the clinical PPH with early transfusion group and the other women with clinical PPH (not 8 transfused or transfused more than 12 hours after PPH diagnosis). In the clinical PPH with 9 early transfusion group, we compared transfusion practices according to mode of delivery and 10 according to cause of PPH, separately in the women with vaginal delivery and caesarean 11 For the 146,781 deliveries during the study period, the RBC transfusion rate for PPH 3 was 0.48±0.04% overall, 0.34±0.03% after vaginal delivery (n=117,606), and 1.03±0.11% 4 after caesarean delivery (n=29,175). PPH with transfusion of at least four RBC units occurred 5 in 0.17% of deliveries. The 701 RBC-transfusion recipients accounted for 7.5±0.5% of 6 women with PPH (n=9365), 5.5% of women with PPH after vaginal birth and 14.4% of 7 women with PPH after caesarean delivery. The RBC transfusion rate was 9.7±0.7% (n=647) 8 among women with clinically diagnosed PPH (n=6660) ( Figure 1 ). 9
RBC transfusion was given to less than half of the women with clinical PPH and 10 haemoglobin levels lower than 7.0 g/dL and to three quarters of women with clinical PPH and 11 haemoglobin levels lower than 6.0 g/dL (Table 1) . Five transfusion-related adverse events 12 were recorded. Only one was severe, with pulmonary oedema requiring ICU admission. 13
Of the 647 women with clinical PPH who required RBC transfusions, 426 (65.8%) 14
received RBCs within 12 hours of the diagnosis (clinical PPH with early transfusion group) 15 and 157 (24.3%) received RBCs later on. In the remaining 64 (9.9%) women, the time from 16 PPH diagnosis to RBC transfusion was unknown. Women with clinical PPH and early 17 transfusion were significantly older and had significantly lower prenatal haemoglobin, higher 18 prevalences of prior PPH, prior caesarean section, multiple pregnancy, caesarean delivery, as 19 well as younger gestational age at delivery and lower birth weight than did the other women 20 with clinical PPH ( Table 2) . 21 22
Transfusion practice and blood loss severity in clinical PPH with early transfusion 23
The following results only concern women with clinical PPH and early transfusion 24 (clinical PPH with early transfusion group, n=426). In this population, more than half of the 25 15 women received a combination of blood products (Table 3 ). In women with PPH after 1 operative vaginal delivery, the median volumes of RBC and FFP units transfused were larger 2 compared to the women with spontaneous vaginal delivery (p=0.001 for RBC and p=0.004 3 for FFP). Overall, 11% of the women with PPH after a vaginal delivery received 10 or more 4 RBC units, and receiving 10 or more RBC units was significantly more common after 5 operative than after spontaneous vaginal delivery (p<0.001, OR: 5.22, 95%CI 2.12-12.82). 6
The use of prohaemostatic agents was significantly more common in the operative vaginal 7 delivery group (p=0.04 between spontaneous and operative vaginal delivery, OR: 3.54, 8 95%CI 1.12-11.18), with 5 out of the 9 women who received recombinant activated factor VII 9 included in this group. 10
The maximal haemoglobin drop was significantly higher after operative than after 11 spontaneous vaginal delivery (p=0.003), as was the rate of conservative surgical procedures 12 (p=0.006, OR: 3.22, 95%CI 1.34-7.76) (Table 4) In PPH after vaginal delivery, coagulation disorders and abnormal placenta insertion 21 were the causes associated with the highest rates of combined blood-products transfusion and 22 of massive transfusion, the largest blood product volumes, the greatest maximal haemoglobin 23 drops, and the highest DIC rate (Table S1 ). In PPH after caesarean delivery, these two causes 24 16 were associated with larger RBC volumes, larger FFP volumes, and higher rates of massive 1 transfusion (Table S2) The RBC transfusion rates we reported is consistent with several findings from previous 10 studies (2, 15, 19, 20) . In a population-based retrospective study from the United States, the 11 overall RBC transfusion rate in the obstetric population was 0.48% (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) all RBC transfusions given within 7 days after delivery. 20
Our data have documented omission of RBC transfusion in a significant proportion of 21 PPH women with haemoglobin levels lower than the recommended trigger. These results 22
suggest that undertransfusion may exist in this context. Moreover, our results suggest that 23 women with PPH in our study may have received smaller volumes of RBCs compared to 24 those in the LEMMoN study, a recent nationwide study of severe acute maternal morbidity 25 performed in the Netherlands (21) . In this study, PPH with transfusion of at least four RBC 1 units occurred for 0.6% of deliveries, three times more frequently than in our study. Failure to 2 recognize severe haemorrhage may result in less frequent RBC transfusion. Omission of RBC 3 transfusion for PPH with low haemoglobin level and small RBC volumes were also found in a 4 previous study of maternal death secondary to PPH in France, where they certainly 5 contributed to the fatal issue (7) . In contrast, a trend towards over-transfusion of women has 6 been reported in the United States (8), the United Kingdom (9) and the Netherlands (22). That 7 the RBC transfusion rate in our study was comparable to that in other countries despite 8 omission of transfusion for PPH with low haemoglobin level may be ascribable to the greater 9 severity of PPH in our population. Various aspects of labour, delivery, and their management, 10 as well as delayed PPH initial treatment and place of delivery, have been shown to increase 11 the risk of severe blood loss in women with PPH (6), and may contribute to increase PPH 12 severity in France. The use of a low transfusion threshold in our study may be ascribable to 13 greater concern among physicians about the risk of maternal alloimmune reactions compared 14 to the risk of acute anaemia in woman who usually have no history of coronary artery disease. 15
In addition, the persistent reluctance to use blood transfusion generated in France by the 16 human immunodeficiency virus epidemic probably made a major contribution. (23). The 17 impacts of low haemoglobin trigger for RBC transfusion on women outcomes has to be 18 evaluated, in order to determine if transfusion guidelines should be strictly followed or if the 19 physicians' attitude is justified. 20
In our study, almost 20% of the women with PPH and early RBC transfusion received 21 fibrinogen concentrates. This proportion appears to be high considering the absence of 22 scientific evidence for an efficacy of this treatment. The use of fibrinogen concentrates could 23 have been influenced by results from experimental laboratory and animal studies that strongly 24 suggested a potent haemostatic effect of fibrinogen substitution (24, 25), and from few 25 19 observational studies. Virally inactivated fibrinogen concentrate offers rapid restoration of 1 fibrinogen levels, with a small volume infusion and minimal preparation time (26). It is 2 effective in treating patients with congenital hypofibrinogenemia (27), but there are very few 3 reports of its use in obstetric hemorrhage. The 2004 French recommendations stated that the 4 use of fibrinogen concentrates in PPH was controversial (18). Before recommending the early 5 use of fibrinogen concentrates in PPH, prospective studies designed to assess its efficacy and 6 tolerance, such as the FIB-TRIAL are required (28). 7
Previous studies have established operative vaginal delivery as a risk factor for PPH 8 (19, 29, 30) . Our results show that operative vaginal delivery is also a risk factor for 9 transfusion among women with PPH. Haemorrhage after operative vaginal delivery required 10 larger blood-product volumes compared to spontaneous vaginal delivery, as previously 11
reported by James et al., without any clear explanation (11) . Operative vaginal delivery was 12 also associated with a significantly higher rate of invasive procedures compared with 13 spontaneous vaginal delivery. These differences seem ascribable to greater blood loss severity 14 in operative than in spontaneous vaginal delivery, as illustrated by the significantly greater 15 haemoglobin drop and higher ICU admission rate. Decreased accuracy of visual blood loss 16 assessment after operative vaginal delivery has been reported (31). Thus, delayed PPH 17 management due to challenges in blood loss assessment, together with the high rate of 18 secondary coagulopathy after operative vaginal delivery --as observed in our study --may 19 contribute to increase blood loss severity in operative vaginal deliveries. 20
As previously reported, coagulation disorders and abnormal placenta insertion were 21 associated with higher blood loss and more transfusion use than other causes of PPH (12, 14, 22 32). These findings suggest that, in the event of operative vaginal delivery, coagulopathy, or 23 abnormal placenta insertion, very close monitoring of postpartum blood loss and of its 24 20 consequences is particularly needed. Point-of-care tests for haemoglobin level and 1 coagulation may be useful tools in these contexts (33). 2
Due to the paucity of data, transfusion guidelines in women are often derived from data 3 and recommendations for trauma patients. We found several similarities in transfusion 4 practices between trauma and obstetrical patients: as with trauma patients, the number of RBC 5 units transfused per woman varied widely; the FFP/RBC ratio in trauma patients was similar 6 to that in our study (34), suggesting that transfusion practices for acute haemorrhage with 7 coagulopathy may be comparable in trauma and PPH (35). Nevertheless, most of the studies 8 of transfusion practices in trauma patients found considerably higher transfusion rates (45% to 9 55%) (34, 36) and larger transfused volumes of RBC (36) than in our women with PPH. 10
Morbidity and mortality rates due to haemorrhagic shock are higher in trauma patients than in 11 women with PPH, with severe acute haemorrhage requiring aggressive transfusion therapy 12 being more common among trauma patients than among women with PPH. Therefore, 13 transfusion guidelines for trauma patients may be relevant only to women with heavy 14
haemorrhage. 15
This study has several strengths. We used a population-based cohort composed of all 16 women who delivered in a predefined geographic area, and whose characteristics were 17 comparable to those of the overall population of women delivering in France (37). These 18 features support the external validity of our results. The large number of deliveries provided 19 robust estimates of transfusion practices in women with PPH and produced sufficient 20 statistical power for comparisons of various obstetrical situations. Moreover, contemporary 21
French guidelines on PPH management (38) and on transfusion in patients with acute 22 haemorrhage (17) are similar to those from other high-resource countries (39, 40), making 23 international comparisons of transfusion practices possible. In the present study, the 24 prospective identification of PPH cases and review of delivery-suite logbooks and 25 21 computerised woman charts probably ensured a high ascertainment rate. Finally, we collected 1 detailed data on transfusion practices in PPH. Three previous prospective population-based 2 studies described transfusion practices but were confined to women with severe PPH 3 requiring invasive second-line treatments such as uterine compression suture, pelvic vessel 4 ligature, interventional radiological techniques (12, 13), and/or hysterectomy (13, 14), which 5 limited the total number of transfused women included. Moreover, in these studies, data on 6 transfusion practices were limited, with no information on the FFP/RBC ratio, time from PPH 7 diagnosis to transfusion, or use of fibrinogen, although these items constitute important 8 information on the quality of transfusion management and may have a major impact on 9 woman outcomes (23, 41). 10
This study has some limitations. The haemoglobin trigger for RBC transfusion was not 11 directly available in the collected data. However, it could be indirectly assessed through the 12 postpartum nadir of haemoglobin, especially among women who were not transfused. Indeed, 13 the absence of RBC transfusion in a great proportion of women with haemoglobin nadir lower 14 than 7g/dL -level recommended as a trigger for RBC transfusion-suggests that the actual 15 haemoglobin trigger for RBC transfusion is frequently lower than recommended. Importantly, 16 this trigger should be interpreted in conjunction with the clinical context. Thus, transfusion 17 requirements differ between women with stable anaemia and those with acute haemorrhage. 18
In the event of active haemorrhage, clinical symptoms of acute anaemia should be given more 19 weight than the haemoglobin trigger. Consequently, using only the haemoglobin to select 20 women for transfusion may be overly restrictive. Nevertheless, most of the studies evaluating 21 the appropriateness of RBC transfusion both in women with stable anaemia and in those with 22 acute haemorrhage relied on the haemoglobin (42, 43) . Another limitation of our study is the 23 absence of maternity unit-specific data on organisational features such as local blood-bank 24 resources, blood availability, and the supply chain. Consequently, we were unable to analyse 25 22 the differences in transfusion practices according to local organisation. We used data from the 1 Pithagore6 trial, which evaluated the impact of an educational intervention for early PPH 2 management on the incidence of severe PPH (16). Designing this trial might have changed 3 transfusion practices in PPH. However, no significant differences were found between the two 4 trial arms regarding the rates of severe PPH and of blood transfusion. Thus, transfusion 5 practices were probably not influenced by the Pithagore6 trial. 
